Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Proteus Syndrome 1

Interventions

Specimen Handling 329 Magnetic Resonance Spectroscopy 238 Biopsy 197 Nivolumab 58 Cyclophosphamide 53 X-Rays 49 Radiation 47 Paclitaxel 47 Carboplatin 47 Cisplatin 46 pembrolizumab 45 Taxes 45 Immunoglobulin G 45 Disulfides 45 Platinum 42 1,2-diaminocyclohexaneplatinum II citrate 42 Radiotherapy 38 Doxorubicin 36 Ipilimumab 32 Gemcitabine 32 atezolizumab 31 CTLA-4 Antigen 31 olaparib 28 fludarabine 28 venetoclax 25 Vincristine 25 Bevacizumab 25 Prednisone 24 cabozantinib 23 Phantoms, Imaging 23

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

NIH × Miransertib × 90 days × Clear all

NCT04316546 2026-06-04

MK-7075 (Miransertib) in Proteus Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting

Proteus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡